Compare RXST & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RXST | DCTH |
|---|---|---|
| Founded | 1997 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.0M | 323.1M |
| IPO Year | 2021 | 2015 |
| Metric | RXST | DCTH |
|---|---|---|
| Price | $6.36 | $8.93 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 4 |
| Target Price | $11.60 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 612.2K | 431.5K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.07 |
| Revenue | ★ $134,479,000.00 | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | $9.57 | $33.15 |
| P/E Ratio | ★ N/A | $129.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.35 | $8.12 |
| 52 Week High | $27.13 | $18.23 |
| Indicator | RXST | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 29.02 | 41.48 |
| Support Level | N/A | $8.90 |
| Resistance Level | $9.11 | $10.17 |
| Average True Range (ATR) | 0.41 | 0.34 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 16.50 | 4.58 |
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.